Skip to content
Subscribe Follow on LinkedIn

Press Release

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

✨ Onyx Summary Kyverna Therapeutics hosted a virtual KOL event outlining progress in its neuroimmunology CAR T franchise, including updated compassionate use data and details of its FDA-aligned Phase 3 trial design for KYV-101 in myasthenia gravis. The registrational KYSA-6 study, enrolling by year-end 2025, will evaluate KYV-101 against standard-of-care to

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

✨ Onyx Summary Lexicon Pharmaceuticals announced that management will participate in fireside chats at Citi’s Biopharma Back to School Conference on September 3, 2025, and the H.C. Wainwright Global Investment Conference on September 8, 2025, with live webcasts available on the company’s investor site. The events provide Lexicon

Recursion to Participate in Upcoming Investor Conferences

Recursion to Participate in Upcoming Investor Conferences

✨ Onyx Summary Recursion Pharmaceuticals announced participation in two upcoming investor conferences: the Citi 2025 BioPharma Back to School Conference on September 3, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025. The company’s engagement underscores its strategy to highlight progress in scaling its Recursion

Belite Bio to Participate in Three Upcoming Investor Conferences

Belite Bio to Participate in Three Upcoming Investor Conferences

✨ Onyx Summary Belite Bio announced that its executive team will present at three major upcoming investor conferences in early September, including Cantor, Morgan Stanley, and H.C. Wainwright. Each presentation will be webcast and available for replay on the company’s investor relations website. These appearances highlight growing investor interest

enGene to Participate in Upcoming Investor Conferences

enGene to Participate in Upcoming Investor Conferences

✨ Onyx Summary enGene Holdings announced its participation in three upcoming investor conferences in September 2025, including the Wells Fargo Healthcare, H.C. Wainwright Global Investment, and Morgan Stanley Global Healthcare conferences. Management will present company updates and discuss progress on detalimogene voraplasmid, its lead non-viral gene therapy candidate for high-risk

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

✨ Onyx Summary Geron Corporation announced it will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference in Boston on September 4, 2025, with a live webcast accessible on its investor website. The appearance highlights Geron’s investor engagement strategy as it advances commercialization of RYTELO® and progresses

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

✨ Onyx Summary Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in three upcoming investor events - Citi’s 2025 Biopharma Back to School Summit, the Wells Fargo Healthcare Conference, and the Morgan Stanley Global Healthcare Conference - where management will engage in one-on-one meetings with investors. The company continues to advance

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

✨ Onyx Summary Legend Biotech announced that CEO Ying Huang, Ph.D., will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 9, 2025. The event will be webcast live via the company’s investor relations site as Legend continues to expand its CAR-T leadership and

Perspective Therapeutics to Participate in Upcoming September Conferences

Perspective Therapeutics to Participate in Upcoming September Conferences

✨ Onyx Summary Perspective Therapeutics announced participation in multiple investor conferences in September 2025, including fireside chats and panel discussions at the Cantor Global Healthcare, Morgan Stanley Global Healthcare, and OPCO Targeted Radiopharmaceutical Therapies Summits in New York. The company’s leadership will engage with investors and industry peers to discuss

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

✨ Onyx Summary Phathom Pharmaceuticals announced that its management team will present at the Cantor Global Healthcare Conference on September 3 and the H.C. Wainwright Global Investment Conference on September 8, 2025, with live webcasts and replays available on the company’s website. Management will also participate in one-on-one investor

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

✨ Onyx Summary Kyverna Therapeutics announced that CEO Warner Biddle will participate in fireside chats at the 2025 Wells Fargo, Morgan Stanley, and H.C. Wainwright Global Healthcare Conferences in early September. The presentations will be webcast live via Kyverna’s investor relations website, with replays available for 90 days. EMERYVILLE,

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

✨ Onyx Summary Phathom Pharmaceuticals clarified that an upcoming Schedule 13D filing by Frazier Life Sciences reflects only administrative reporting changes and does not reduce Frazier’s ownership in the company. By affirming that no shares have been sold, Phathom underscores continued investor commitment at a pivotal time in advancing its